Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment

Current Treatment Options in Rheumatology

Volumn 2, Issue 3, 2016, Pages 252-269

  Young, Amber ^a   Namas, Rajaie ^a   Dodge, Carole ^b   Khanna, Dinesh ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acro osteolysis; Arthralgias; Calcinosis; Digital ulcers; Hand impairment; Hand involvement; Inflammatory arthritis; Joint contractures; Puffy hands; Raynaud s phenomenon; Scleroderma; Skin sclerosis; Systemic sclerosis; Tendon friction rubs

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; AMLODIPINE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLCHICINE; CORTICOSTEROID; DILTIAZEM; DNA TOPOISOMERASE INHIBITOR; FLUOXETINE; GLYCERYL TRINITRATE; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; MINOCYCLINE; MYCOPHENOLATE MOFETIL; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROBENECID; RITUXIMAB; SILDENAFIL; TADALAFIL; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; WARFARIN;

ACROOSTEOLYSIS; ARTHRALGIA; CALCINOSIS; CLINICAL TRIAL (TOPIC); DAILY LIFE ACTIVITY; FINGER ULCER; HAND DISEASE; HAND FUNCTION; HAND IMPAIRMENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JOINT CONTRACTURE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANGE OF MOTION; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TENOSYNOVITIS;

EID: 85031709034     PISSN: None     EISSN: 21986002     Source Type: Journal    
DOI: 10.1007/s40674-016-0052-9     Document Type: Review

References (57)

1. Sandqvist G, Eklund M, Akesson A, Nordenskiold U. Daily activities and hand function in women with scleroderma. Scand J Rheumatol. 2004;33(2):102–7.
2. Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology. 2012;51(8):1347–56. doi:10.1093/rheumatology/kes041.
3. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010;37(7):1488–501. doi:10.3899/jrheum.091165.
4. Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):103–9. doi:10.1136/annrheumdis-2014-205295.
5. Morrisroe KB, Nikpour M, Proudman SM. Musculoskeletal manifestations of systemic sclerosis. Rheum Dis Clin North Am. 2015;41(3):507–18. doi:10.1016/j.rdc.2015.04.011.
6. Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol. 2008;22(2):339–50. doi:10.1016/j.berh.2008.01.008.
7. Elhai M, Guerini H, Bazeli R, Avouac J, Freire V, Drape JL, et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res. 2012;64(8):1244–9. doi:10.1002/acr.21668.
8. Abdel-Magied RA, Lotfi A, AbdelGawad EA. Magnetic resonance imaging versus musculoskeletal ultrasonography in detecting inflammatory arthropathy in systemic sclerosis patients with hand arthralgia. Rheumatol Int. 2013;33(8):1961–6. doi:10.1007/s00296-013-2665-8.
9. Low AH, Lax M, Johnson SR, Lee P. Magnetic resonance imaging of the hand in systemic sclerosis. J Rheumatol. 2009;36(5):961–4. doi:10.3899/jrheum.080795.
10. Sandqvist G, Nilsson JA, Wuttge DM, Hesselstrand R. Development of a modified hand mobility in scleroderma (HAMIS) test and its potential as an outcome measure in systemic sclerosis. J Rheumatol. 2014;41(11):2186–92. doi:10.3899/jrheum.140286.
11. Mouthon L, Carpentier PH, Lok C, Clerson P, Gressin V, Hachulla E, et al. Ischemic digital ulcers affect hand disability and pain in systemic sclerosis. J Rheumatol. 2014;41(7):1317–23. doi:10.3899/jrheum.130900. Prospective, multicenter study evaluating the functional effect of SSc-related DU with results indicating an association of DU with pain and hand disability.
12. Gordon JK, Berrocal VJ, Girish G, Zhang M, Hatzis C, Assassi S, et al. Reliability and validity of the total joint count and swollen joint count in early diffuse systemic sclerosis [abstract]. Arthritis Rheumatol. 2015;67:suppl 10. http://acrabstracts.org/abstract/reliability-and-validity-of-the-total-joint-count-and-swollen-joint-count-in-early-diffuse-systemic-sclerosis/. Accessed December 8, 2015.
13. Lorand V, Czirjak L, Minier T. Musculoskeletal involvement in systemic sclerosis. Presse Med. 2014;43(10 Pt 2):e315–28. doi:10.1016/j.lpm.2014.03.027.
14. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol. 2011;38(2):289–96. doi:10.3899/jrheum.100361.
15. Young A, Khanna D. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol. 2015;27(3):241–8. doi:10.1097/BOR.0000000000000172. A systematic review discussing the pharmacologic and non-pharmacologic management of systemic sclerosis.
16. Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72(7):1217–20. doi:10.1136/annrheumdis-2012-202657.
17. Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis. 2007;66(7):977–9. doi:10.1136/ard.2006.060111.
18. Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol. 2005;32(4):642–8.
19. Avouac J, Guerini H, Wipff J, Assous N, Chevrot A, Kahan A, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis. 2006;65(8):1088–92. doi:10.1136/ard.2005.044602.
20. Jewett LR, Hudson M, Malcarne VL, Baron M, Thombs BD, Canadian Scleroderma Research Group. Sociodemographic and disease correlates of body image distress among patients with systemic sclerosis. PLoS One. 2012;7(3):e33281. doi:10.1371/journal.pone.0033281.
21. Anandacoomarasamy A, Englert H, Manolios N, Kirkham S. Reconstructive hand surgery for scleroderma joint contractures. J Hand Surg. 2007;32(7):1107–12. doi:10.1016/j.jhsa.2007.06.011.
22. Gilbart MK, Jolles BM, Lee P, Bogoch ER. Surgery of the hand in severe systemic sclerosis. J Hand Surg. 2004;29(6):599–603. doi:10.1016/j.jhsb.2004.03.013.
23. Balint Z, Farkas H, Farkas N, Minier T, Kumanovics G, Horvath K, et al. A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-68–74.
24. Radic M, Martinovic Kaliterna D, Ljutic D. The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis. Clin Exp Rheumatol. 2006;24(4):407–12.
25. Ashida R, Ihn H, Mimura Y, Jinnin M, Asano Y, Kubo M, et al. Clinical features of scleroderma patients with contracture of phalanges. Clin Rheumatol. 2007;26(8):1275–7. doi:10.1007/s10067-006-0490-0.
26. Poole JL, Macintyre NJ, Deboer HN. Evidence-based management of hand and mouth disability in a woman living with diffuse systemic sclerosis (scleroderma). Physiotherapy Canada Physiotherapie Canada. 2013;65(4):317–20. doi:10.3138/ptc.2012-40. A case study emphasizing various occupational hand therapy techniques used for hand impairment in systemic sclerosis.
27. Fox P, Chung L, Chang J. Management of the hand in systemic sclerosis. J Hand Surg. 2013;38(5):1012–6. doi:10.1016/j.jhsa.2013.02.012. quiz 7.
28. Rose S, Varga J. Diffuse palpable tendon friction rubs in a patient with seronegative erosive polyarthritis. J Clin Rheumatol. 2010;16(6):300–1. doi:10.1097/RHU.0b013e3181ef6ee1.
29. Steen VD, Medsger Jr TA. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum. 1997;40(6):1146–51. doi:10.1002/1529-0131(199706)40:6<1146::AID-ART19>3.0.CO;2-9.
30. Stoenoiu MS, Houssiau FA, Lecouvet FE. Tendon friction rubs in systemic sclerosis: a possible explanation—an ultrasound and magnetic resonance imaging study. Rheumatology. 2013;52(3):529–33. doi:10.1093/rheumatology/kes307.
31. Khanna PP, Furst DE, Clements PJ, Maranian P, Indulkar L, Khanna D, et al. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology. 2010;49(5):955–9. doi:10.1093/rheumatology/kep464.
32. Domsic RT, Nihtyanova SI, Wisniewski SR, Fine MJ, Lucas M, Kwoh CK et al. Derivation and external validation of a 5-year mortality prediction rule for patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2015. doi:10.1002/art.39490.
33. Dore A, Lucas M, Ivanco D, Medsger Jr TA, Domsic RT. Significance of palpable tendon friction rubs in early diffuse cutaneous systemic sclerosis. Arthritis Care Res. 2013;65(8):1385–9. doi:10.1002/acr.21964.
34. Nagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology. 2015;54(11):1944–53. doi:10.1093/rheumatology/keu285.
35. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44(8):1841–7. doi:10.1002/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8.
36. Garcia de la Pena Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, Roman Ivorra JA, et al. Efficacy of Raynaud’s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int. 2015;35(9):1447–59. doi:10.1007/s00296-015-3241-1.
37. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology. 2001;40(9):1038–43.
38. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696–9. doi:10.1136/annrheumdis-2012-202836.
39. Wall LB, Stern PJ. Nonoperative treatment of digital ischemia in systemic sclerosis. J Hand Surg. 2012;37(9):1907–9. doi:10.1016/j.jhsa.2012.02.009.
40. Silva I, Almeida J, Vasconcelos C. A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev. 2015;14(2):140–52. doi:10.1016/j.autrev.2014.10.009.
41. Matucci-Cerinic M, Krieg T, Guillevin L, Schwierin B, Rosenberg D, Cornelisse P, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2015-208121.
42. Young A, Khanna D. Systemic sclerosis: commonly asked questions by rheumatologists. J Clin Rheumatol. 2015;21(3):149–55. doi:10.1097/RHU.0000000000000232.
43. Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res. 2013;65(9):1460–71. doi:10.1002/acr.22018.
44. Bongi SM, Del Rosso A, Passalacqua M, Miccio S, Cerinic MM. Manual lymph drainage improving upper extremity edema and hand function in patients with systemic sclerosis in edematous phase. Arthritis Care Res. 2011;63(8):1134–41. doi:10.1002/acr.20487.
45. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476–81. doi:10.1136/ard.2010.136929.
46. Avouac J, Mogavero G, Guerini H, Drape JL, Mathieu A, Kahan A, et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis. 2011;70(4):630–3. doi:10.1136/ard.2010.134304.
47. Johnstone EM, Hutchinson CE, Vail A, Chevance A, Herrick AL. Acro-osteolysis in systemic sclerosis is associated with digital ischaemia and severe calcinosis. Rheumatology. 2012;51(12):2234–8. doi:10.1093/rheumatology/kes214.
48. Valenzuela A, Chung L. Calcinosis: pathophysiology and management. Curr Opin Rheumatol. 2015;27(6):542–8. doi:10.1097/BOR.0000000000000220. A recent review on available treatment for calcinosis, which indicates pharmacologic agents have variable outcomes, and surgical excision is a key treatment option for calcinosis.
49. Chander S, Gordon P. Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol. 2012;24(2):158–64. doi:10.1097/BOR.0b013e32834ff5cd.
50. Sandqvist G, Akesson A, Eklund M. Evaluation of paraffin bath treatment in patients with systemic sclerosis. Disabil Rehabil. 2004;26(16):981–7. doi:10.1080/09638280410001702405.
51. Mancuso T, Poole JL. The effect of paraffin and exercise on hand function in persons with scleroderma: a series of single case studies. J Hand Ther. 2009;22(1):71–7. doi:10.1016/j.jht.2008.06.009. quiz 8.
52. Seeger MW, Furst DE. Effects of splinting in the treatment of hand contractures in progressive systemic sclerosis. Am J Occup Ther. 1987;41(2):118–21.
53. Poole JL, Skipper B, Mendelson C. Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis. Clin Rheumatol. 2013;32(9):1393–8. doi:10.1007/s10067-013-2282-7.
54. Bongi SM, Del Rosso A, Galluccio F, Sigismondi F, Miniati I, Conforti ML, et al. Efficacy of connective tissue massage and Mc Mennell joint manipulation in the rehabilitative treatment of the hands in systemic sclerosis. Clin Rheumatol. 2009;28(10):1167–73. doi:10.1007/s10067-009-1216-x.
55. Del Papa N, Di Luca G, Sambataro D, Zaccara E, Maglione W, Gabrielli A, et al. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. Cell Transplant. 2015;24(11):2297–305. doi:10.3727/096368914X685636.
56. Granel B, Daumas A, Jouve E, Harle JR, Nguyen PS, Chabannon C, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2015;74(12):2175–82. doi:10.1136/annrheumdis-2014-205681.
57. Guillaume-Jugnot P, Daumas A, Magalon J, Jouve E, Nguyen PS, Truillet R, et al. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Rheumatology. 2015. doi:10.1093/rheumatology/kev323. An example of an encouraging novel-therapeutic approach for hand impairment in SSc using autologous adipose-derived stromal vascular fraction (ADSVF).